Aptahem AB Logo

Aptahem AB

Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions involving a combination of coagulation, inflammation, and tissue damage. The company's lead candidate, Apta-1, is in clinical development with a primary indication for sepsis, a condition with a significant unmet medical need and high mortality. Apta-1 features a unique multi-mechanistic profile to address the complex pathology of sepsis. Aptahem's technology leverages synthetically produced aptamers, which offer a highly specific and low-immunogenicity alternative to traditional antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptahem AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea 475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America OSTX
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan 4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom OCTHF
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America PCRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.